Creatine Supplementation Prior to Strength Exercise Training Is Not Superior in Preventing Muscle Mass Loss Compared with Standard Nutritional Recommendations in Females After Bariatric Surgery: A Pilot Study.

BACKGROUND: This study examines whether creatine supplementation combined with strength training mitigates muscle mass loss in women during early rehabilitation post-bariatric surgery, as its effectiveness remains untested in this context. METHODS: Fifteen women (37.8 ± 9.6 years; BMI, 38.8 ± 5.6 kg/m2) completed the intervention (creatine group = 7; placebo group = 8). Both groups followed a strength training program three times a week for 8 weeks. The dosage for both the creatine and placebo was 8 g prior to each exercise session. Body weight, skeletal muscle mass, fat mass, handgrip strength, and physical activity levels were measured before and after the intervention. RESULTS: The creatine group showed a reduction of 9.5 ± 1.5 kg in body weight, with a 0.72 ± 0.6 kg decrease in muscle mass and an 8.64 ± 1.2 kg reduction in fat mass. The placebo group had a reduction of 9.6 ± 3.5 kg in body weight, with a 0.6 ± 1.2 kg decrease in muscle mass and an 8.88 ± 3.2 kg reduction in fat mass, without significant differences between groups (p > 0.05). CONCLUSION: The pre-session strength exercise training creatine supplementation is not superior to placebo regarding body weight and fat mass losses and the attenuation of muscle mass loss during the first weeks of rehabilitation following bariatric surgery.

Early Exercise Through Telerehabilitation After Bariatric Surgery: Is It Feasible?

PURPOSE: The feasibility of early telerehabilitation after bariatric surgery is unknown. The objective of this study was to assess the feasibility and perception of engaging in the online exercise protocol in patients during the first month after bariatric surgery. MATERIAL AND METHODS: A total of 67 patients, enrolled in a telerehabilitation program following bariatric surgery, completed a survey assessing their perception of the intensity, discomfort, and safety during exercise sessions. RESULTS: Forty percent of participants began exercising between 5 and 10 days after surgery. Seventy-one percent of patients did not experience discomfort during the first month of exercise, and those who reported discomfort mainly mentioned dizziness and abdominal pain. No significant differences were found in the presence of discomfort among different types of surgeries performed. There was a significant difference in the presence of discomfort between patients who started exercising before and after 15 days of surgery, with less discomfort reported in the group that started after 15 days. Ninety-eight percent of patients felt safe during online exercise sessions. Most participants perceived the intensity of the sessions as moderate. The most frequently mentioned benefits of exercise were increased energy, mood, and feeling more active. CONCLUSION: Telerehabilitation conducted during the first month after bariatric surgery was feasible and well tolerated by patients, providing a safe alternative for those patients who face difficulties with in-person interventions.

[Maximum aerobic power output in overweight and obese individuals]. / Potencia aeróbica máxima en el obeso: Valores de referencia.

BACKGROUND: The evaluation of physical fitness is important to determine workloads and to assess the effectiveness of exercise interventions in obese people. AIM: To determine the maximum aerobic power output (MAPO) in overweight and obese individuals and to establish reference parameters for the Chilean population. MATERIAL AND METHODS: One hundred five men and 218 women performed a cycle ergometer test up to 85% of their maximum heart rate. MAPO was determined by linear extrapolation of the theoretical maximum heart rate. RESULTS: Among men, MAPO values were 234.9 ± 48.4 w for body mass index (BMI) values between 30 and 34.9 kg/m2, 235.1 ± 69.7 w for BMI between 35 and 39.9 kg/m2, 270.2 ± 86.5 w for BMI over 40 kg/m2. MAPO relative values were 2.27 ± 0.5, 2.16 ± 0.6 and 1.96 ± 0.8 w/kg, respectively. Among women, MAPO was 172.6 ± 36.1 w for a BMI < 30 kg/m2, 169.2 ± 39.4 w for BMI between 30 and 34.9 kg/m2, 179.5 ± 48.8 w f179.5 ± 48.8 w for BMI between 35 and 39.9 kg/m2 and 202.3 ± 57.3 w for BMI of 40 kg/m2 or over. The relative values were 2.33 ± 0.5; 2.02 ± 0.5; 1.91 ± 0.5 and 1.81 ± 0.5 w / kg (p < 0.05). CONCLUSIONS: MAPO estimation with a cycle ergometer test is well tolerated in overweight and obese individuals. MAPO decreased along with BMI increments in women. No association between BMI and MAPO in men was observed.

Potencia aeróbica máxima en el obeso: Valores de referencia / Maximum aerobic power output in overweight and obese individuals

Background: The evaluation of physical fitness is important to determine workloads and to assess the effectiveness of exercise interventions in obese people. Aim: To determine the maximum aerobic power output (MAPO) in overweight and obese individuals and to establish reference parameters for the Chilean population. Material and Methods: One hundred five men and 218 women performed a cycle ergometer test up to 85% of their maximum heart rate. MAPO was determined by linear extrapolation of the theoretical maximum heart rate. Results: Among men, MAPO values were 234.9 ± 48.4 w for body mass index (BMI) values between 30 and 34.9 kg/m2, 235.1 ± 69.7 w for BMI between 35 and 39.9 kg/m2, 270.2 ± 86.5 w for BMI over 40 kg/m2. MAPO relative values were 2.27 ± 0.5, 2.16 ± 0.6 and 1.96 ± 0.8 w/kg, respectively. Among women, MAPO was 172.6 ± 36.1 w for a BMI < 30 kg/m2, 169.2 ± 39.4 w for BMI between 30 and 34.9 kg/m2, 179.5 ± 48.8 w f179.5 ± 48.8 w for BMI between 35 and 39.9 kg/m2 and 202.3 ± 57.3 w for BMI of 40 kg/m2 or over. The relative values were 2.33 ± 0.5; 2.02 ± 0.5; 1.91 ± 0.5 and 1.81 ± 0.5 w / kg (p < 0.05). Conclusions: MAPO estimation with a cycle ergometer test is well tolerated in overweight and obese individuals. MAPO decreased along with BMI increments in women. No association between BMI and MAPO in men was observed.

Endosymbiotic Mycobacterium chelonae in a Vermamoeba vermiformis strain isolated from the nasal mucosa of an HIV patient in Lima, Peru.

In March 2010, a 35 year-old HIV/AIDS female patient was admitted to hospital to start treatment with Highly Active Antiretroviral Therapy (HAART) since during a routine control a dramatic decrease in the CD4(+) levels was detected. At this stage, a nasal swab from each nostril was collected from the patient to include it in the samples for the case study mentioned above. Moreover, it is important to mention that the patient was diagnosed in 2009 with invasive pneumococcal disease, acute cholecystitis, pancreatitis and pulmonary tuberculosis. The collected nasal swabs from both nostrils were positive for Vermamoeba vermiformis species which was identified using morphological and PCR/DNA sequencing approaches. Basic Local Alignment Search Tool (BLAST) homology and phylogenetic analysis confirmed the amoebic strain to belong to V.vermiformis species. Molecular identification of the Mycobacterium strain was carried out using a bacterial universal primer pair for the 16S rDNA gene at the genus level and the rpoB gene was amplified and sequenced as previously described to identify the Mycobacterium species (Shin et al., 2008; Sheen et al., 2013). Homology and phylogenetic analyses of the rpoB gene confirmed the species as Mycobacterium chelonae. In parallel, collected swabs were tested by PCR and were positive for the presence of V.vermiformis and M.chelonae. This work describes the identification of an emerging bacterial pathogen,M.chelonae from a Free-Living Amoebae (FLA) strain belonging to the species V.vermiformis that colonized the nasal cavities of an HIV/AIDS patient, previously diagnosed with TB. Awareness within clinicians and public health professionals should be raised, as pathogenic agents such as M.chelonae may be using FLA to propagate and survive in the environment.